Trial Profile
To assess reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix Hexa) at 2, 4 and 6 months of age.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections; Pneumonia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 21 Dec 2006 New trial record.